Vascular cytochrome P450 enzymes: Physiology and pathophysiology

被引：86

作者：

Fleming, Ingrid ^{[1
]}

机构：

[1] Univ Frankfurt, Inst Kardiovsc Physiol, Vasc Signalling Grp, D-60590 Frankfurt, Germany

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2008年 / 18卷 / 01期

关键词：

D O I：

10.1016/j.tcm.2007.11.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cytochrome P450 epoxygenases and the soluble epoxide hydrolase are enzymes that regulate the cellular content of bioactive epoxides such as the epoxyeicosatrienoic acids derived from arachidonic acid. Epoxyeicosatrienoic acids are recognized as lipid mediators that participate in vascular signaling processes such as the acute regulation of vascular tone and the processes of inflammation and angiogenesis.

引用

页码：20 / 25

页数：6

共 57 条

[1] Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo [J].

Ai, Ding ;

Fu, Yi ;

Guo, Deliang ;

Tanaka, Hiromasa ;

Wang, Nanping ;

Tang, Chaoshu ;

Hammock, Bruce D. ;

Shyy, John Y. -J. ;

Zhu, Yi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (21) :9018-9023

[2] Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans [J].

Bellien, J ;

Joannides, R ;

Iacob, M ;

Arnaud, P ;

Thuillez, C .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (04) :H1347-H1352

[3] Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation [J].

Bellien, Jeremy ;

Iacob, Michele ;

Gutierrez, Laurence ;

Isabelle, Marc ;

Lahary, Agnes ;

Thuillez, Christian ;

Joannides, Robinson .

HYPERTENSION, 2006, 48 (06) :1088-1094

[4] Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma [J].

Bergheim, I. ;

Wolfgarten, E. ;

Bollschweiler, E. ;

Hoelscher, A. H. ;

Bode, C. ;

Parlesak, A. .

WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (07) :997-1002

[5] EDHF:: bringing the concepts together [J].

Busse, R ;

Edwards, G ;

Félétou, M ;

Fleming, I ;

Vanhoutte, PM ;

Weston, AH .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (08) :374-380

[6] Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction [J].

Chehal, MK ;

Granville, DJ .

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2006, 84 (01) :15-20

[7] Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation [J].

Davis, BB ;

Thompson, DA ;

Howard, LL ;

Morisseau, C ;

Hammock, BD ;

Weiss, RH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2222-2227

[8] The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension [J].

Dreisbach, AW ;

Japa, S ;

Sigel, A ;

Parenti, MB ;

Hess, AE ;

Srinouanprachanh, SL ;

Rettie, AE ;

Kim, H ;

Farin, FM ;

Hamm, LL ;

Lertora, JJL .

AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (10) :1276-1281

[9] Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors [J].

Fang, X ;

Hu, SM ;

Watanabe, T ;

Weintraub, NL ;

Snyder, GD ;

Yao, JR ;

Liu, Y ;

Shyy, JYJ ;

Hammock, BD ;

Spector, AA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (01) :260-270

[10] Inhibition of cytochrome P4502C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease [J].

Fichtlscherer, S ;

Dimmeler, S ;

Breuer, S ;

Busse, R ;

Zeiher, AM ;

Fleming, I .

CIRCULATION, 2004, 109 (02) :178-183

← 1 2 3 4 5 6 →